A Phase 1 Clinical Trial to Determine the Safety and Tolerability of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic or Locally Advanced Unresectable Breast Cancer

Trial Profile

A Phase 1 Clinical Trial to Determine the Safety and Tolerability of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic or Locally Advanced Unresectable Breast Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs Cirmtuzumab (Primary) ; Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2017 Planned End Date changed from 1 Apr 2019 to 1 Jan 2020.
    • 10 May 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Jan 2019.
    • 10 May 2017 Planned initiation date changed from 1 Aug 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top